(Q44459454)

3 December 2017

title

Are children with idiopathic nephrotic syndrome at risk for metabolic bone disease? (English)

1 reference

idiopathic nephrotic syndrome

3 December 2017

1 reference

1 reference

Sanjeev Gulati

1

1 reference

3 December 2017

Madan Godbole

2

1 reference

3 December 2017

Uttam Singh

3

1 reference

3 December 2017

Kiran Gulati

4

1 reference

3 December 2017

Arvind Srivastava

5

1 reference

3 December 2017

publication date

1 June 2003

1 reference

American Journal of Kidney Diseases

3 December 2017

published in

1 reference

3 December 2017

volume

41

1 reference

3 December 2017

issue

6

1 reference

3 December 2017

page(s)

1163-1169

1 reference

Bone histology in patients with nephrotic syndrome and normal renal function

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900348-2

7 January 2021

Calcium and vitamin D metabolism in children with nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900348-2

7 January 2021

Vitamin D metabolites in childhood nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900348-2

7 January 2021

Steroid-induced osteoporosis in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900348-2

7 January 2021

A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900348-2

7 January 2021

Inhaled corticosteroids, bone density, and risk of fracture

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900348-2

7 January 2021

Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: a double-blind study on the high-dose, long-term effects of prednisone versus deflazacort

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900348-2

7 January 2021

Influence of steroid medication on bone mineral density in children with nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900348-2

7 January 2021

Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephrotic patients receiving high-dose glucocorticoid and one-cycle etidronate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900348-2

7 January 2021

Bone Mineral Content in Nephrotic Children on Long-Term, Alternate-Day Prednisone Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900348-2

7 January 2021

Is it correct to supplement patients with nephrotic syndrome with vitamin D and calcium?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900348-2

7 January 2021

The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900348-2

7 January 2021

Steroid response pattern in Indian children with nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900348-2

7 January 2021

Intravenous pulse cyclophosphamide--a new regime for steroid-resistant minimal change nephrotic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900348-2

7 January 2021

Pulse cyclophosphamide therapy in frequently relapsing nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900348-2

7 January 2021

Bone mass in healthy children: measurement with quantitative DXA.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900348-2

7 January 2021

Clinical utility of bone mass measurements in adults: consensus of an international panel. The Society for Clinical Densitometry

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900348-2

7 January 2021

Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900348-2

7 January 2021

Possible mechanism of impaired calcium and vitamin D metabolism in nephrotic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900348-2

7 January 2021

Vitamin D metabolism in nephrotic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900348-2

7 January 2021

Use of corticosteroids in nephrology - risk and prevention of osteoporosis induction

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900348-2

7 January 2021

Management of corticosteroid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900348-2

7 January 2021

Bone histomorphometry in glucocorticoid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900348-2

7 January 2021

Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900348-2

7 January 2021

10.1016/S0272-6386(03)00348-2

Identifiers

DOI

1 reference

3 December 2017

1 reference